Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$4.24
-4.9%
$6.01
$4.13
$11.16
$326.54M0.912.92 million shs2.99 million shs
Amgen Inc. stock logo
AMGN
Amgen
$294.39
-5.0%
$304.18
$253.30
$346.85
$158.15B0.532.73 million shs5.25 million shs
Endo International plc stock logo
ENDP
Endo International
$0.45
$0.28
$7.07
$141K1.1528.19 million shs9,967 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$737.56
-6.5%
$848.36
$711.40
$972.53
$699.33B0.343.33 million shs5.29 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$22.99
-5.4%
$25.87
$22.95
$31.54
$130.27B0.6739.46 million shs79.83 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$22.62
-6.6%
$29.32
$21.53
$81.86
$2.54B0.843.93 million shs6.56 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%-20.30%-24.15%-41.60%-54.36%
Amgen Inc. stock logo
AMGN
Amgen
0.00%-4.09%-7.37%+12.70%+7.28%
Endo International plc stock logo
ENDP
Endo International
0.00%0.00%0.00%0.00%+50.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-10.09%-19.19%-5.68%-4.99%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-8.77%-12.27%-13.54%-15.57%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%-11.81%-21.13%-47.26%-71.16%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
2.0574 of 5 stars
3.41.00.00.01.83.30.6
Amgen Inc. stock logo
AMGN
Amgen
4.2873 of 5 stars
2.24.03.33.93.52.50.6
Endo International plc stock logo
ENDP
Endo International
0.3199 of 5 stars
0.00.00.03.50.61.70.0
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8972 of 5 stars
3.45.03.34.03.32.51.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9667 of 5 stars
3.33.04.24.23.33.33.1
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.2991 of 5 stars
4.51.00.04.72.83.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.89
Moderate Buy$20.83391.35% Upside
Amgen Inc. stock logo
AMGN
Amgen
2.48
Hold$314.046.68% Upside
Endo International plc stock logo
ENDP
Endo International
0.00
N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.7236.90% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9238.86% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$95.18320.79% Upside

Current Analyst Ratings Breakdown

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/26/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
3/18/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/14/2025
Altimmune, Inc. stock logo
ALT
Altimmune
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/11/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Amgen Inc. stock logo
AMGN
Amgen
Johnson Rice
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$294.00
(Data available from 4/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$20K16,326.97N/AN/A$2.75 per share1.54
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.73$29.50 per share9.98$10.93 per share26.93
Endo International plc stock logo
ENDP
Endo International
$2.99B0.00N/A0.06($13.60) per share0.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.53$12.02 per share61.34$15.05 per share49.01
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.05$3.60 per share6.38$15.81 per share1.45
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.34N/AN/AN/A-199,076.92%-55.81%-50.60%5/8/2025 (Estimated)
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$7.5538.9913.762.6312.24%176.32%11.71%5/1/2025 (Estimated)
Endo International plc stock logo
ENDP
Endo International
-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7162.9923.701.4023.51%85.24%16.19%5/1/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4116.317.590.6412.62%19.47%8.09%4/29/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.00N/AN/AN/AN/A-11.93%-11.57%4/23/2025 (Estimated)

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Amgen Inc. stock logo
AMGN
Amgen
$4.18N/AN/AN/A$8.05 billionN/A
5/1/2025N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
4/29/2025N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.67N/AN/AN/A$14.43 billionN/A
4/23/2025N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.34N/AN/AN/AN/AN/A
2/27/2025Q4 2024
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 million
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.27-$0.32-$0.05-$0.32N/AN/A
2/4/2025Q4 2024
Amgen Inc. stock logo
AMGN
Amgen
$5.04$5.31+$0.27$1.16$8.87 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Amgen Inc. stock logo
AMGN
Amgen
$9.523.23%+8.53%126.09%14 Years
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.81%+15.21%51.24%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.48%+2.50%121.99%16 Years
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/4/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.05%5/16/20255/16/20256/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
16.87
16.87
Amgen Inc. stock logo
AMGN
Amgen
9.62
1.26
0.95
Endo International plc stock logo
ENDP
Endo International
N/A
1.86
1.62
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
36.47
36.47

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Endo International plc stock logo
ENDP
Endo International
80.39%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
Amgen Inc. stock logo
AMGN
Amgen
0.69%
Endo International plc stock logo
ENDP
Endo International
1.20%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5077.01 million68.21 millionOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000537.21 million533.50 millionOptionable
Endo International plc stock logo
ENDP
Endo International
3,103235.14 million232.32 millionNo Data
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.25 million106.20 millionOptionable

Recent News About These Companies

The Smartest Biotech Stocks to Buy With $50
Modern medical technology system and devices - stock image
Which Healthcare Stock Is the Best Buy Right Now?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$4.24 -0.22 (-4.93%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$4.26 +0.02 (+0.47%)
As of 04/4/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Amgen stock logo

Amgen NASDAQ:AMGN

$294.39 -15.46 (-4.99%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$291.78 -2.61 (-0.89%)
As of 04/4/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Endo International stock logo

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$737.56 -51.53 (-6.53%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$717.25 -20.31 (-2.75%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer stock logo

Pfizer NYSE:PFE

$22.99 -1.30 (-5.35%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$22.94 -0.05 (-0.22%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$22.62 -1.60 (-6.61%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$22.02 -0.60 (-2.63%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.